**Table 1**. Patients and tumor characteristics overall and according to treatment group.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | Overall | Preoperative chemotherapy  | Preoperative radiotherapy  | Concurrent chemo-radiotherapy  |   |
|   | N = 233 | N = 46 | N = 99 | N = 88 | SMD |
|   | n (%) | n (%) | n (%) | n (%) |   |
| Sex |   |   |   |   | 0,072 |
| Male | 134 (57.5) | 28 (60.9) | 55 (55.6) | 51 (58.0) |   |
| Female | 99 (42.5) | 18 (39.1) | 44 (44.4) | 37 (42.0) |   |
| Age |   |   |   |   | 0,862 |
| Median (1st and 3rd quartile) | 64.08 (56.41; 71.64) | 58.67 (48.60; 63.44) | 71.04 (63.97; 76.96) | 60.83 (50.32; 66.44) |   |
| Tumor site |   |   |   |   | 0,239 |
| Upper limb | 49 (21.0) | 10 (21.7) | 26 (26.3) | 13 (14.8) |   |
| Trunk wall | 37 (15.9) | 6 (13.0) | 18 (18.2) | 13 (14.8) |   |
| Lower limb | 147 (63.1) | 30 (65.2) | 55 (55.6) | 62 (70.5) |   |
| Depth |   |   |   |   | 0,252 |
| Superficial | 12 (5.2) | 2 (4.3) | 9 (9.1) | 1 (1.1) |   |
| Deep | 221 (94.8) | 44 (95.7) | 90 (90.9) | 87 (98.9) |   |
| Tumor size |   |   |   |   | 0,444 |
| Median (1st and 3rd quartile) | 12.00 (8.00; 16.00) | 11.00 (8.00; 16.75) | 9.00 (7.00; 15.50) | 14.50 (11.00; 17.25) |   |
| Histology |   |   |   |   | 0,334 |
| Myxofibrosarcoma | 66 (28.3) | 8 (17.4) | 39 (39.4) | 19 (21.6) |   |
| Undifferentiated pleomorphic sarcoma  | 167 (71.7) | 38 (82.6) | 60 (60.6) | 69 (78.4) |   |
| FNCLCC grade |   |   |   |   | 0,685 |
| I/II | 64 (27.5) | 4 (8.7) | 50 (50.5) | 10 (11.4) |   |
| III | 169 (72.5) | 42 (91.3) | 49 (49.5) | 78 (88.6) |   |
| Recist |   |   |   |   | 0,373 |
| Partial response | 56 (25.2) | 11 (29.7) | 22 (22.7) | 23 (26.1) |   |
| Stable disease | 137 (61.7) | 18 (48.6) | 59 (60.8) | 60 (68.2) |   |
| Progression disease | 29 (13.1) | 8 (21.6) | 16 (16.5) | 5 (5.7) |   |
| Radiotherapy dose |   |   |   |   | --- |
| Median (1st and 3rd quartile) | 50.00 (50.00; 50.00) | --- | 50.00 (50.00; 50.00) | 50.00 (50.00; 50.00) |   |
| Residual viable tumor  |   |   |   |   | 0,629 |
| Median (1st and 3rd quartile) | 10.00 (5.00; 50.00) | 45.00 (2.75; 70.00) | 20.00 (10.00; 60.00) | 10.00 (5.00; 20.00) |   |
| Residual viable tumor  |   |   |   |   | 0,340 |
| 0% | 22 (9.4) | 10 (21.7) | 5 (5.1) | 7 (8.0) |   |
| >0% | 211 (90.6) | 36 (78.3) | 94 (94.9) | 81 (92.0) |   |
| Residual viable tumor  |   |   |   |   | 0,303 |
| > 5% | 156 (67.0) | 33 (71.7) | 75 (75.8) | 48 (54.5) |   |
| ≤ 5% | 77 (33.0) | 13 (28.3) | 24 (24.2) | 40 (45.5) |   |
| Surgical margin |   |   |   |   | 0,212 |
| R0 | 197 (84.5) | 38 (82.6) | 79 (79.8) | 80 (90.9) |   |
| R1 | 36 (15.5) | 8 (17.4) | 20 (20.2) | 8 (9.1) |   |
| Recurrence |   |   |   |   | 0,681 |
| Local relapse | 11 (13.1) | 4 (26.7) | 6 (17.6) | 1 (2.9) |   |
| Distant metastasis | 67 (79.8) | 9 (60.0) | 24 (70.6) | 34 (97.1) |   |
| Local relapse and distant metastasis | 6 (7.1) | 2 (13.3) | 4 (11.8) | 0 (0.0) |   |